Skip to main content
. 2021 Apr 27;13(9):2112. doi: 10.3390/cancers13092112

Figure 2.

Figure 2

LAG-3 expression correlates with prognostic factors in CLL. (A) LAG-3 surface expression was evaluated on leukemic cells from patients with CLL (n = 61) categorized by cytogenetics abnormalities by flow cytometry; (B) LAG-3 surface expression on leukemic cells in patients stratified by cytogenetics abnormalities (n = 61): no marker (no abnormalities), favorable cytogenetics (del(13q)) and adverse cytogenetics (patients with del(11q), del(17p) and/or trisomy 12 owing or not del(13q)) is shown; (C) In silico analysis (GSE4392) of LAG3 mRNA expression in leukemic cells from ZAP70-CD38- (good prognosis) and ZAP70+CD38+ (poor prognosis) patients; (D–G) Evaluation of LAG-3 expression on leukemic cells from patients with mutated (m-IGHV) or unmutated (um-IGHV) IGHV; Comparison of LAG-3 expression patients (MFI ± SEM) (E) and percentage (F) in patients with del(13q) are shown (n = 61); (G) Sera levels of sLAG-3 in 28 patients with mutated and unmutated IGHV status are depicted; (H) In silico analysis of LAG3 mRNA expression in patients stratified by driver mutations in CLL using cBioportal. * p < 0.05 and ** p < 0.01.